



# SPAIN 2025

FEBRUARY 27 & 28



MD Anderson  
~~Cancer Center~~  
Madrid • España



MD Anderson  
~~Cancer Center~~  
Fundación • España

# SOHO SPAIN 2025

## A Society of Hematologic Oncology Regional/Satellite Meeting

SOHO is a global society designed specifically for clinicians, research scientists and related health care professionals who specialize in the research and treatment of patients with hematologic malignancies. SOHO's mission is to expedite worldwide research and education through the exchange of scientific information.

The Society of Hematologic Oncology (SOHO) was established as a non-profit corporation in 2012 with aims to promote worldwide research, education, prevention, clinical studies, and optimal patient care in all aspects of hematologic malignancies and related disorders. Since that time, nearly 9,500 members from 110 countries have joined the society from around the globe. To become a SOHO member, go to [www.soho.click/join](http://www.soho.click/join) and access the resources available exclusively to members. SOHO membership is free-of-charge. If you have any questions, you can contact SOHO membership at [admin@isoho.org](mailto:admin@isoho.org).

**FEBRUARY 27 & 28**

# SOHO

## Meetings

- The SOHO meetings have no parallel general sessions so that delegates may attend all sessions in sequential order. In addition, presentations are limited to the 'latest advances' allowing all topics to be covered in only 2 days.
- Based on input from the SOHO Board of Directors, formal guidelines were established for Ambassadors to hold SOHO meetings in different parts of the world. The following summarizes the requirements for regional/satellite SOHO meetings:
  - Maximum of one "Annual" Meeting per Country or Region.
  - The proposed program must be reviewed and approved by the SOHO Board.

## DOSSIER

**GENERAL  
INFORMATION**

**GENERAL  
PROGRAM**

**SPONSORS**

**Index**

**FEBRUARY 27 & 28**

## Honorary President

**Dr. Hagop Kantarjian**

**Dra. María Victoria Mateos**

## Directors

**Dr. Guillermo García-Manero**

University of Texas MD Anderson Cancer Center, Houston, USA

**Dr. Adolfo de la Fuente Burguera**

MD Anderson Cancer Center Madrid – Hospiten, Spain

## Spanish Scientific committee

- **Dra. Ana Sureda**
- **Dra. María Díaz Campelo**
- **Dr. Carlos Fernández de Larrea**
- **Dr. Pau Montesinos**
- **Dr. Carlos Panizo**
- **Dr. Ramón García-Sanz**
- **Dr. Fernando Martín Moro**
- **Dr. Valentín García Gutiérrez**
- **Dr. Francesc Bosch**

## International Scientific committee

- **Dr. Alessandro Isidori**
- **Dr. Claudio Cerchione**
- **Dr. Elías Jabbour**
- **Dr. Naval Daver**

**FEBRUARY 27 & 28**

- **Sessions divided by disease or subject:**

AML, ALL, MDS, CML, CLL, MPN, MM, NHL, HL, Cellular Therapy (CT).

- **Variety of presentation formats such as:**

"state-of-the-art" reviews, "how I manage," "treatment approaches," "current updates in management of...", debates (with audience pre- and post-debate polls), case presentations, "next questions" (where do we go next in research/clinical research to improve outcomes for patients?)

- **Pre-dinner symposiums: February 27**
- **Breakfast symposiums: February 27 and 28**
- **Lunch symposiums: February 27 and 28**

## GENERAL SESSIONS

- Acute Lymphoblastic Leukemia
  - Acute Myeloid Leukemia
    - Cellular Therapy
- Chronic Lymphocytic Leukemia
  - Chronic Myeloid Leukemia
- Diffuse Large B-Cell Lymphoma
  - Follicular Lymphoma
  - Mantle Cell Lymphoma
  - Multiple Myeloma
- Myelodysplastic Syndromes
- Myeloproliferative Neoplasm

**FEBRUARY 27 & 28**

## PROGRAM 27

- **9:30h - 9:40h Welcome** **Phil Scheinberg** São Jose Hospital, Portuguese Charity. *São Paulo, Brazil*  
**Guillermo García Manero** University of Texas MD Anderson Cancer Center, *Houston, USA*  
**Adolfo de la Fuente** MD Anderson Cancer Center Madrid – Hospiten. *Madrid, Spain*

### 1. Multiple myeloma: Controversies in treatment

Moderator: Carlos Fernández de Larrea, Hospital Clinic of Barcelona. *Barcelona, Spain*

Moderator: Verónica González de la Calle, H. C. U. of Salamanca. *Salamanca, Spain*

- **9:40h - 10:10h First-line treatment: Bortezomib, lenalidomide, and anti-CD38 for all?** **Aurore Perrot**  
Toulouse University Hospital. *Toulouse, France*
- **10:10h - 10:30h How to treat at relapse? Antibody-based approaches** **Niels van de Donk**  
Amsterdam University Medical Center. *Amsterdam, Netherlands*
- **10:30h - 10:50h How to treat at relapse? CAR-T cell-based strategies** **Luis Gerardo Rodriguez**  
Clinical Hospital of Barcelona. *Barcelona, Spain*
- **10:50h - 11:20h Discussion:** All speakers and moderators

## PROGRAM 27

### 1. Multiple myeloma: Controversies in treatment

Moderator: Carlos Fernández de Larrea, Hospital Clinic of Barcelona. *Barcelona, Spain*

Moderator: Verónica González de la Calle, University Hospital of Salamanca. *Salamanca, Spain*

• **11:20h- 11:40h**    **Breaking news** **Claudio Cerchione**

IRCCS Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori" – IRST. *Meldola, Italy*

• **11:40h - 11:55h**    **Coffee Break**

## PROGRAM 27

### 2. Chronic Myeloid Leukemia

Moderator: Valentín García Gutiérrez, Ramón y Cajal University Hospital. *Madrid, Spain*

Moderator: Alicia Senin, Hospital Del Mar. *Barcelona, Spain*

- **11:55h - 12:15h** **Prognostic implications of cancer-associated mutations in CML** Gonzalo Carreño  
12 de Octubre University Hospital. *Madrid, Spain*
- **12:15h - 12:35h** **First-line therapy updates in CML patients** Valentín García Gutiérrez  
Ramón y Cajal University Hospital. *Madrid, Spain*
- **12:35h - 12:55h** **Treatment discontinuation in CML: Who, how, and when?** Santiago Osorio  
Gregorio Marañón, University Hospital - Madrid. *Madrid, Spain*
- **12:55h - 13:10h** **Discussion**

## PROGRAM 27

### 3. Myelodysplastic Syndromes (MDS)

Moderator: María Díez Campelo, University of Salamanca. Salamanca, Spain

Moderator: Adolfo de la Fuente, MD Anderson Cancer Center Madrid - Hospiten. Madrid, Spain

- **13:10h - 13:30h Rethinking classification and prognosis in MDS** Rami Komrokji  
Moffit Cancer Center. *Houston, USA*
- **13:30h - 13:50h How to avoid transfusion dependence in low-risk MDS** Valeria Santini  
University of Florence Medical School in Florence. *Florence, Italy*
- **13:50h - 14:10h Targeted therapy and new targets in high-risk MDS** Guillermo García-Manero  
University of Texas MD Anderson Cancer Center. *Houston, USA*
- **14:10h - 14:25h Discussion**

## PROGRAM 27

### IDEOGEN Symposium Program

- **14:25h - 15:10h** **Advances in the management of T lymphomas: from the disease to clinical solutions**  
*Ana García Noblejas* Princess Hospital. *Madrid, Spain*  
*Alejandra Blum* Campo Grande Hospital, Recoletas Group. *Valladolid, Spain*  
*Beatriz Urrego* General Hospital of Catalunya. *Barcelona, Spain*

## PROGRAM 27

• **15:10h - 15:55h Lunch** Sponsored by GSK

### **4. Acute Myeloid Leukemia (AML) NOVEL TARGETED THERAPIES FOR AML**

Moderator: Adolfo de la Fuente, MD Anderson Cancer Center Madrid - Hospiten. *Madrid, Spain*

Moderator: Pau Montesinos, La Fe Polytechnic University Hospital. *Valencia, Spain*

• **15:55h - 16:15h Menin inhibitors for AML. What does the future look like?** **Cristina Papayannidis**  
IRCCS Azienda Ospedaliero-Universitaria di Bologna. *Bologna, Italy*

• **16:15h - 16:35h Emerging triplets and doublets with FLT3 inhibitors** **Juan Bergua**  
San Pedro de Alcántara Hospital. *Cáceres, Spain*

• **16:35h - 16:55h Current developments of IDH inhibitors: beyond ivosidenib for unfit AML patients** **Rebeca Rodriguez**  
La Fe Health Research Institute IIS La Fe. *Valencia, Spain*

• **16:55h - 17:10h Discussion**

• **17:10h - 17:25h Coffee Break**

## PROGRAM 27

### 5. Lymphoma 1

Moderator: Juan Fernando García García - MD Anderson Cancer Center Madrid - Hospiten. *Madrid, Spain*

Moderator: Ramon García Sanz, Gregorio Marañón General University Hospital. *Madrid, Spain*

Moderator: Fernando Martín Moro, Ramón y Cajal University Hospital. *Madrid, Spain*

- **17:25h - 17:45h Lymphoma Classification How to develop a Future Unified Taxonomy** Miguel Ángel Piris  
Fundación Jiménez Díaz. *Madrid, Spain*
- **17:45h - 18:05h Towards targeted treatments on the front line** Alejandro Martín García Sancho  
University Hospital of Salamanca. *Salamanca, Spain*
- **18:05h - 18:25h Diffuse Large B-cell lymphoma sequencing of therapies in the relapse setting** Miguel Canales  
University Clinic of Navarra. *Pamplona, Spain*
- **18:25h - 18:45h Multidisciplinary approach in cutaneous T cell lymphoma** Miriam López Parra  
University Hospital of Salamanca. *Salamanca, Spain*
- **18:45h - 19:00h Discussion**

## PROGRAM 27

### **CLL Symposium pre-official dinner sympo** **Advancing individualization of treatment**

Moderator: Javier de la Serna, 12 de Octubre University Hospital. *Madrid, Spain*

• **19:00h - 20:00h**

**Highlights CLL** *Lucrecia Yáñez Marqués de Valdecilla*  
University Hospital - IDIVAL University of Cantabria. *Cantabria, Spain.*

**Discussion table: Individualization of treatment: Beyond Cytogenetics**

*Jose Antonio García Vela* Puerta De Hierro University Hospital. *Madrid, Spain*

*Almudena Navarro* University Hospital of Salamanca. *Salamanca, Spain*

• **21:00h**

**Dinner** Sponsored by SANOFI  
Restaurant: Fortuny Home Club: Address: C. de Fortuny, 34

## PROGRAM 28

### SERB Symposium Program

Moderator: Jaime Verdú Amorós, Hospital University Valencia. Valencia, Spain

- **8:00h - 8:05h** **Welcome. Challenges in the management of patients treated with HDMTX** **Adolfo de la Fuente**  
MD Anderson Cancer Center Madrid – Hospiten. *Madrid, Spain*
- **8:05h - 8:25h** **Review of guidelines and protocols for the management of adult patients treated with HDMTX** **Anna Torrent Catarineu** | Catalan Institute of Oncology | Clinical Hematology | Germans Trias i Pujol Hospital. *Barcelona, Spain*
- **8:25h - 8:50h** **Glucarpidase (Voraxaze®) in acute MTX toxicity. Early diagnosis of delayed methotrexate elimination. “A European consensus recommendation on the treatment of late elimination of methotrexate: supportive measures, leucovorin rescue and glucarpidase treatment.”** **Thais Murciano Carrillo** – Vall d’Hebron University Hospital. *Barcelona, Spain*
- **8:50h - 9:00h** **Questions and discussion**

## PROGRAM 28

• **9:00h - 9:10h - 1. Introduction to the treatment landscape in CLL**

Moderator: Francesc Bosch, Vall d'Hebron Hospital. *Barcelona, Spain*

Moderator: Juan Marquet Palomanes, Ramón y Cajal University Hospital. *Madrid, Spain*

Moderator: José Francisco Tomás, La Moraleja University Hospital / Virgen del Mar University Hospital. *Madrid, Spain*

• **9:10h - 9:20h Continuous vs. time-limited treatment** - Previous voting

• **9:20h - 9:30h Continuous vs. time-limited treatment** - In favor of continuous strategies **Javier Loscertales**  
*La Princesa University Hospital. Madrid, Spain*

• **9:30h - 9:40h Continuous vs. time-limited treatment** - In favor of time-limited strategies (**Streaming Session**)  
**Othman Al-Sawaf** University Hospital Cologne. *Cologne, Germany*

• **9:40h - 9:50h Continuous vs. time-limited treatment** - Discussion

• **9:50h - 10:00h Continuous vs. time-limited treatment** - Final voting

## PROGRAM 28

### 1. Introduction to the treatment landscape in CLL

Moderator: Francesc Bosch, Vall d'Hebron Hospital. *Barcelona, Spain*

Moderator: Juan Marquet Palomanes, Ramón y Cajal University Hospital. *Madrid, Spain*

Moderator: José Francisco Tomás, La Moraleja University Hospital / Virgen del Mar University Hospital. *Madrid, Spain*

• **10:00h - 10:15h Sequencing treatment after front-line BTKi**

**Almudena Navarro** University Hospital of Salamanca. *Salamanca, Spain*

• **10:15h - 10:30h Sequencing treatment after time-limited therapy** **Lucrecia Yáñez**

Marqués de Valdecilla University Hospital - IDIVAL University of Cantabria. *Cantabria, Spain*

• **10:30h - 10:45h Richter transformation** **Pau Abrisqueta** Vall d'Hebron Hospital. *Barcelona, Spain*

• **10:45h - 11:00h Coffee break**

## PROGRAM 28

### 2.Negative Philadelphia Myeloproliferative Neoplasms

Moderator: Valentín García Gutiérrez, Ramón y Cajal University Hospital *Madrid, Spain*

Moderator: Lucía Pérez Lamas, Puerta de Hierro University Hospital. *Madrid, Spain*

- **11:00h - 11:20h** **New developments in diagnosis and molecular monitoring of Philadelphia-negative myeloproliferative neoplasms** Beatriz Bellosillo Hospital del Mar. *Barcelona, Spain*
- **11:20h - 11:40h** **Interferon in Polycythemia Vera, how, when and to whom?** Miguel Piris  
Ramón y Cajal University Hospital. *Madrid, Spain*
- **11:40h - 12:00h** **Optimizing Treatment for Myelofibrosis: A Personalized Approach** Francesca Palandri  
IRCCS Azienda Ospedaliero-Universitaria di Bologna. *Bologna, Italy*
- **12:00h - 12:15h** **Discussion**

## PROGRAM 28

### 2. Negative Philadelphia Myeloproliferative Neoplasms

Moderator: Valentín García Gutiérrez, Ramón y Cajal University Hospital *Madrid, Spain*

Moderator: Lucía Pérez Lamas, Puerta de Hierro University Hospital. *Madrid, Spain*

#### • 12:15h - 12:35h **Breaking news**

Moderador: **Carlos Montalban** MD Anderson Cancer Center Madrid – Hospiten. *Madrid, Spain*

Moderador: **Ramon García Sanz** Gregorio Marañón General University Hospital, *Madrid, Spain*

Moderador: **Sara Alonso Álvarez** Hospital Universitario Central de Asturias. ISPA. IUOPA. *Oviedo, Spain*

**Luis Fayad** MD Anderson Cancer Center. *Houston, USA*

## PROGRAM 28

### 3.Lymphoma 2

Moderator: Carlos Montalban, MD Anderson Cancer Center Madrid - Hospiten. *Madrid, Spain*

Moderator: Ramón García Sanz, Gregorio Marañón General University Hospital. *Madrid, Spain*

Moderator: Sara Alonso Álvarez, Central University Hospital of Asturias. ISPA. IUOPA. *Oviedo, Spain*

• **12:35h - 12:55h Advanced Hodgkin lymphoma: can we improve first-line treatment? (Streaming Session)**

**Peter Borchmann** University Hospital of Cologne. *Cologne, Germany*

• **12:55h - 13:15h Choosing Between a BTK Inhibitor & Car T-Cell Therapy in RR MCL** **Ana Marín Niebla**

Vall d'Hebron University Hospital. *Barcelona, Spain.*

• **13:15h - 13:35h Discussion**

## PROGRAM 28

### DAIICHI SANKIO Symposium Program

#### How molecular information guide treatment decisions

Moderator: Adolfo de la Fuente MD Anderson Cancer Center Madrid – Hospiten. *Madrid, Spain*

Moderator: Claudia Núñez-Torrón Stoch Infanta Sofía University Hospital. *Madrid, Spain*

• **13:35h - 14:20h Genetic study in myeloblastic leukemia at diagnosis** Margarida Coucelo  
Pediatric Hospital of Coimbra. *Coimbra, Portugal*

**The evolving role of FLT3 inhibitors for AML** Adolfo de la Fuente  
MD Anderson Cancer Center Madrid – Hospiten. *Madrid, Spain*

• **14:20h - 15:30h Lunches**

## PROGRAM 28

### 4. Transplant and Cell Therapy

Moderator: Ana Alarcón Tomás, Puerta de Hierro University Hospital. *Madrid, Spain*

Moderator: Carlos Panizo, Donostia University Hospital. *San Sebastián, Spain*

Moderator: Ana Sureda, Catalan Institute of Oncology (ICO). *Barcelona, Spain*

- **15:30h - 15:50h CART cells in acute myeloblastic leukemia** Nela Klein Hospital Clinic Barcelona. *Barcelona, Spain*
- **15:50h - 16:10h Post-CART relapses in patients with B lymphoma: Mechanisms of resistance and potential therapeutic strategies.** Roni Shouval Memorial Sloan Kettering Cancer Center, New York, USA
- **16:10h - 16:30h Role of hematopoietic stem cell transplantation in lymphomas in 2025** Leyre Bento Son Espases Hospital. *Palma de Mallorca, Spain*
- **16:30h - 16:45h Discussion**
- **16:45h - 17:00h Coffee**

## PROGRAM 28

### 5.Lymphoma 3

Moderator: Carlos Montalban, MD Anderson Cancer Center Madrid – Hospiten. *Madrid, Spain*

Moderator: Alejandro Bobes, MD Anderson Cancer Center Madrid – Hospiten. *Madrid, Spain*

Moderrator: Carlos Panizo, Donostia University Hospital. *San Sebastián, Spain*

• **17:00h - 17:20h Follicular Lymphoma management algorithm in 2025** Armando López Guillermo  
*Hospital Clinic of Barcelona. Barcelona, Spain*

• **17:20h - 17:40h POD24 it's not all the same** Ana Muntañola  
*Hospital de la Santa Creu i Sant Pau. Barcelona, Spain*

• **17:40h - 17:50h Discussion**

• **17:50h - 18:10h Breaking news in acute leukemia**

Moderator: Luis Pedro Monteiro ULS São José. *Lisbon, Portugal*

Moderator: Carlos Jiménez Chillón Gregorio Marañón University Hospital. *Madrid, Spain*

**Leucemia Mieloblastica** Naval Daver MD Anderson Cancer Center. *Houston, US*

**Leucemia Linfoblastica** Elías Jabbour MD Anderson Cancer Center. *Houston, US*

## PROGRAM 28

### **6. Acute Myeloid Leukemia ( AML ) From clinical trials to real-life data in AML**

Moderator: Adolfo de la Fuente, MD Anderson Cancer Center Madrid – Hospiten. *Madrid, Spain*

Moderator: Pau Montesinos, Hospital Universitari i Politècnic La Fe. *Valencia, Spain*

- **18:10h - 18:30h Real world practice with Venetoclax-based regimens for unfit AML** **Stephane de Botton**  
*Institut Gustave Roussy. Paris, France*
- **18:30h - 18:50h International experience with CPX-351 for high-risk fit AML** **Teresa Bernal**  
*Central University Hospital of Asturias. Oviedo, Spain*
- **18:50h - 19:05h Discussion**
- **19:05h - 19:10h Farewell** **Phil Scheinberg** *São Jose Hospital, Portuguese Charity. São Paulo, Brazil*  
**Giullermo García Manero** *University of Texas MD Anderson Cancer Center. Houston, USA*  
**Adolfo de la Fuente** *MD Anderson Cancer Center Madrid – Hospiten, Spain. Madrid, Spain*

# REGISTRATION fee

**SOHO SPAIN 2025 Congress is exclusively in-person, not online**

Register on the website [www.sohospain.org](http://www.sohospain.org)

**400 Euros**

€

- 21% VAT not included
- The registration fee includes participation in all sessions, certificate of attendance and continuing education, access to the post-meeting webcast as well as coffee breaks, lunches, and dinner.
- The allocation of on-site registrations will be subject to capacity limitations.

**FEBRUARY 27 & 28**

## SPONSORS

**PLATINUM**

AstraZeneca 

**SERVIER**   
moved by you

**GOLD**

 **SERB**  
Pharmaceuticals

## SPONSORS

### SILVER

abbvie

*Lilly*

**Johnson  
& Johnson**

**GSK**

**Roche**



Daiichi-Sankyo

## SPONSORS

### BRONZE

**KYOWA KIRIN**

 **MENARINI**  
group

**Stemline**  
A Menarini Group Company

 **Jazz** Pharmaceuticals

 **Bristol Myers Squibb**

 **GILEAD** |  **Kite**

 **IDEOGEN**

 **Pfizer**

 **BeiGene**

## SPONSORS

## COLLABORATOR





FEBRUARY 27 & 28



MDAnderson  
~~Cancer~~ Center  
Madrid • España



MDAnderson  
~~Cancer~~ Center  
Fundación • España

